Thomas Jorg Mehrling

This inventor holds 25 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Cancer Treatment. Top assignees: Purdue Pharmaceutical Products L.p., Purdue Pharma L.p.. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Jorg Mehrling. Retrieved from https://idiyas.com/inventor/thomas-jorg-mehrling

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 1.7

ph-index = 8

Forward Citations = 162(Granted Patents)

Location History:

Basel, CH (2018 - 2024)
Riehen, CH (2022 - 2024)

Company Filing History:

13 out of 24

Purdue Pharmaceutical Products L.p.

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

Multiple Myeloma

Hodgkin Lymphoma

Pharmaceutical Combinations

Brain Cancer

TNBC

Tinostamustine

T-Cell Malignant Disease

Glucocorticoid

Humanized Antibodies

Sarcoma

Ovarian Cancer

Receptor Tyrosine Kinase

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653808 - Compounds for treating multiple myeloma (2026-06-16),

2. 12440475 - Hodgkin lymphoma therapy (2025-10-14),

3. 12403130 - Pharmaceutical combinations for treating cancer (2025-09-02),

4. 12377076 - Compounds for treating lymphoma or a T-cell malignant disease (2025-08-05),

5. 12370178 - Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia (2025-07-29),

6. 12370177 - Compounds for treating brain cancer (2025-07-29),

7. 12303492 - Compounds for treating TNBC (2025-05-20),

8. 12257237 - Tinostamustine for use in treating sarcoma (2025-03-25),

9. 12064417 - Combination comprising a glucocorticoid and EDO-S101 (2024-08-20),

10. 12048688 - Pharmaceutical combinations for treating cancer (2024-07-30),

11. 11918558 - Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia (2024-03-05),

12. 11896583 - Tinostamustine for use in treating ovarian cancer (2024-02-13),

13. 11786509 - Compounds for treating TNBC (2023-10-17),

14. 11766424 - Hodgkin lymphoma therapy (2023-09-26),

15. 11576899 - Tinostamustine for use in treating sarcoma (2023-02-14),

Title: Thomas Jorg Mehrling - Innovative Inventor from Basel

Introduction: Thomas Jorg Mehrling is a renowned inventor hailing from Basel, Switzerland, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Thomas Jorg Mehrling's latest patents include advancements in renewable energy systems, medical devices, and artificial intelligence technologies.

Career Highlights: With a career spanning over two decades, Thomas Jorg Mehrling has established himself as a pioneer in the innovation landscape, holding numerous patents and receiving recognition for his impactful inventions.

Collaborations: Throughout his career, Thomas Jorg Mehrling has collaborated with leading research institutions, universities, and multinational companies to bring his innovative ideas to life and create real-world solutions.

Conclusion: Thomas Jorg Mehrling's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.